Cancer News and Research

Latest Cancer News and Research

Olympus receives FDA clearance for Articulating HD 3D Laparoscopic Surgical Video System

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Articulating HD 3D Laparoscopic Surgical Video System.

From Evident Corporation - Life Sciences 10 Apr 2013

St. Mary Medical Center completes expansion of Emergency Department and Trauma Center

St. Mary Medical Center has completed Phase 2 of its Emergency Department and Trauma Center expansion. To celebrate this event, a ribbon-cutting ceremony was held Tuesday, April 9, at 9 a.m., in the newly renovated Emergency Department.

10 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Viewpoints: Looking for the budget's true bottom line; The debate on Plan B reignited; Medicare cuts have impact

President Obama will release his overdue budget on Wednesday. It will doubtless project a reduction in the federal budget deficit - a projection that journalists, commentators and policy makers should ignore.

10 Apr 2013

OTraces completes Phase II testing for blood test that detects breast cancer

OTraces, Inc., a Maryland-based biotech company developing blood tests for cancer diagnosis, announces completion of Phase II testing for a blood test that screens women for breast cancer.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Elekta's Versa HD system accelerates radiation delivery to new levels

Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

From Elekta 10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life.

10 Apr 2013

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.

10 Apr 2013

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Scientists from UCLA's Fielding School of Public Health led by Julia Heck, an assistant researcher in the school's epidemiology department and a member of UCLA's Jonsson Comprehensive Cancer Center, have found a possible link between exposure to traffic-related air pollution and several childhood cancers.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation.

9 Apr 2013

Cancer News and Research

Latest Cancer News and Research

Olympus receives FDA clearance for Articulating HD 3D Laparoscopic Surgical Video System

St. Mary Medical Center completes expansion of Emergency Department and Trauma Center

MD Anderson scientists demonstrate new way to restore tumor suppression

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Viewpoints: Looking for the budget's true bottom line; The debate on Plan B reignited; Medicare cuts have impact

OTraces completes Phase II testing for blood test that detects breast cancer

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Elekta's Versa HD system accelerates radiation delivery to new levels

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Findings could help develop new ways to predict risks of tobacco-associated cancers

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New study suggests that Ranibizumab can be potential prophylaxis for PVR

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

New immunotherapies are seldom developed for childhood cancer

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Understanding the DNA Damage Response in Innate Immunity eBook

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Newsletters you may be interested in